Ann Surg. 2022 Jan 25. doi: 10.1097/SLA.0000000000005395. Online ahead of print.
ABSTRACT
OBJECTIVE: This study investigates the use of serum DUPAN-2 in predicting the PC progression in CA19-9 nonsecretors.
BACKGROUND: Although we previously reported that serum CA19-9 >500 U/mL is a poor prognostic factor and an indication for enhanced neoadjuvant treatment, there is not a biomarker surrogate that equivalently predicts prognosis for CA19-9 nonsecretors.
METHODS: We evaluated consecutive PC patients who underwent pancreatectomy from 2005 to 2019. All patients were categorized as either nonsecretor or secretor (CA19-9 ≤ or >2.0 U/mL).
RESULTS: Of the 984 resected PC patients, 94 (9.6%) were nonsecretors and 890 (90.4%) were secretors. The baseline characteristics were not statistically different between the 2 groups except for the level of DUPAN-2 (720 vs. 100 U/mL, P < 0.001). Survival curves after resection were similar between the 2 groups (29.4 months vs. 31.3 months, P = 0.900). Survival curves of patients with DUPAN-2 >2000 U/mL in the nonsecretors and patients with CA19-9 >500 U/mL in the secretors were nearly equivalent as well (hazard ratio 2.08 vs. 1.89). In the multivariate analysis, DUPAN-2 >2000 U/mL (hazard ratio 2.53, P = 0.010) was identified as independent prognostic factor after resection.
CONCLUSION: DUPAN-2 >2000 U/mL in CA19-9 nonsecretors can be an unfavorable factor that corresponds to CA19-9 >500 U/mL in CA19-9 secretors which is an indicator for enhanced neoadjuvant treatment. The current results shed light on the subset of nonsecretors with poor prognosis that were traditionally categorized in a group with a more favorable prognosis group.
PMID:35081567 | DOI:10.1097/SLA.0000000000005395